Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited has filed an ATM supplementary prospectus with the U.S. Securities and Exchange Commission to extend its At-the-market (ATM) funding facility with H.C. Wainwright & Co., LLC. This strategic move allows Immuron to raise approximately US$2,847,954, providing the company with financial flexibility and an efficient mechanism to raise additional equity capital in response to operational needs and market opportunities.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. One of its key products, Travelan®, is designed to reduce the risk of travelers’ diarrhea and is available as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the U.S.
YTD Price Performance: 16.46%
Average Trading Volume: 244,435
Technical Sentiment Signal: Buy
Current Market Cap: A$24.68M
See more data about IMC stock on TipRanks’ Stock Analysis page.